BioPharma Resources

Therapeutic area

Rare and genetic disease

Lysosomal storage disorders, inborn errors of metabolism and other rare conditions. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

26

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

16

Industry-sponsored

Recruiting Phase 3

13

Industry-sponsored

Recruiting Phase 4 (post-approval)

5

Industry-sponsored

Recent approvals

All
  • Emcitate (Tiratricol) · Rare Thyroid NovelPriority reviewOrphanSep 28, 2026

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INC Breakthrough therapyPriority reviewOrphanJun 24, 2026
  • Idvynso (Doravirine, Islatravir) · Msd NovelApr 20, 2026

    To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMar 24, 2026

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Yuviwel (Navepegritide) · Ascendis NovelAccelerated approvalPriority reviewOrphanFeb 27, 2026

    To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma Ab NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanFeb 23, 2026

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Redemplo (Plozasiran Sodium) · Arrowhead NovelBreakthrough therapyOrphanNov 18, 2025

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INC NovelBreakthrough therapyPriority reviewOrphanNov 3, 2025

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Forzinity (Elamipretide Hydrochloride) · Stealth Biotheraps NovelAccelerated approvalPriority reviewOrphanSep 19, 2025

    To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

  • Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INC NovelOrphanAug 21, 2025

    To prevent attacks of hereditary angioedema

  • Sephience (Sepiapterin) · Ptc Therap NovelOrphanJul 28, 2025

    To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet

  • Ekterly (Sebetralstat) · Kalvista NovelOrphanJul 3, 2025

    To treat acute attacks of hereditary angioedema

  • Andembry (Garadacimab-Gxii) · Csl Behring LLC NovelOrphanJun 16, 2025

    To prevent attacks of hereditary angioedema

  • Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025

    For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INC NovelBreakthrough therapyPriority reviewOrphanDec 19, 2024

    To treat familial chylomicronemia syndrome

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • BrenipatideLY3537031Phase 313 trials

    Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major

  • PovorcitinibINCB054707, INCB54707Phase 312 trials

    Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials

    Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia

  • GlucocorticoidsPhase 37 trials

    Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease

  • IMVT-1402Phase 37 trials

    Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • AND017Phase 36 trials

    Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia

  • ElriterceptTAK-226, KER-050Phase 36 trials

    Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia

  • LUM-201Phase 36 trials

    Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight

Largest recruiting Phase 3 trials

All

More: Rare and genetic disease news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.